FDA "FLEXIBILITY" IN DETERMINING ACCEPTABLE OTC ORAL ANTISEPTIC RESEARCH PROGRAMS
This article was originally published in The Tan Sheet
Executive Summary
FDA "FLEXIBILITY" IN DETERMINING ACCEPTABLE OTC ORAL ANTISEPTIC RESEARCH PROGRAMS is requested by the Non-prescription Drag Manufacturers Association in Aug. 8 comments on FDA's tentative final monograph on oral antiseptic products. NDMA "requests the agency to adopt a flexible, case-by-case approach when determining the requirements for testing an active ingredient," the comments state.